Proteasome Deubiquinating Inhibitor Screening
AssigneeVivolux AB
InventorsSlavica Brnjic, Padraig D'Arcy, Rolf Larsson, Stig Linder
Life of this patent
Estimating the term…
Abstract
A method for screening a compound to determine whether the compound is a proteasome deubiquinating inhibitor of high specificity comprises contacting the compound with human 19S regulatory particles (19S RP) of 26S proteasome and determining whether the compound inhibits activity of deubiquinating (DUB) enzymes UCHL5 and USP14; inhibition of UCHL5 and USCP14 activities indicates that the compound is a proteasome deubiquinating inhibitor of high specificity.
Claims6
A method for screening a compound to determine whether the compound is a proteasome deubiquinating inhibitor of high specificity, the method comprising contacting the compound with human 19S regulatory particles (19S RP) of 26S proteasome and determining whether the compound inhibits activity of deubiquinating (DUB) enzymes UCHL5 and USP14, wherein inhibition of UCHL5 and USP14 activities indicates that the compound is a proteasome deubiquinating inhibitor of high specificity.
Dependencies are inferred from the claim text.